China will adjust tariffs on imported U.S. products from 12:01 p.m. Wednesday, the Customs Tariff Commission of the State Council announced on Tuesday.

The immunoassay segment accounts about 35% of the market, with no growth compared to the previous year. Domestic brands account for over 35%.

Qiagen and OncXerna Therapeutics said on Monday that they have signed a master agreement to develop a next-generation sequencing companion diagnostic for navicixizumab, which OncXerna is developing as a treatment for patients with ovarian cancer.

For many metastatic cancer patients, a one-time whole-genome analysis of a biopsy may be enough to identify their treatment options, a new study has found.

Castle Biosciences reported after the close of the market on Monday that its first quarter revenues rose 79 percent year over year, thanks to more than double the number of tests delivered during the quarter.

Quidel reported after the close of the market Thursday that its second quarter revenues fell 12 percent year over year, which the firm attributed to decreased demand for its Sofia and PCR COVID-19 assays, as well as lower demand for influenza products.

Meridian Bioscience reported on Friday morning a 25 percent year-over-year decline in its fiscal third quarter revenues, one year after recording record highs in Q3 2020.

A newly finalized guidance from the US Food and Drug Administration (FDA) helps manufacturers understand how to use near-infrared (NIR)-based analyses in evaluating drug attributes.

Sansure biology and Zhuhai Baolian signed the termination agreement of the share transfer agreement on August 5, 2021.

2021 ranking features 143 Chinese companies, 122 U.S. companies, and 53 Japanese companies. 6 in vitro diagnostic companies on the list.

On August 3, Sinopharm listed its 30% equity interest in Maixin Biotechnology on the China Beijing Equity Exchange at a price of 947.5 million yuan. Beijing Strong Biotechnologies, Inc. (hereinafter referred to as BSBE) said they would fight for the acquisition.

DiaSorin said on Friday that its second quarter revenues rose 20 percent year over year, driven by strength in molecular diagnostic test sales.